299 related articles for article (PubMed ID: 26281143)
1. Beyond Criteria and Definitions: Outcome of a Standardized Antibody-Mediated Rejection Protocol with a Diagnostic Schema Different from the Banff 2009 Criteria.
Rendulic T; Ramon DS; Killen PD; Samaniego-Picota M; Park JM
Clin Transpl; 2014; ():179-87. PubMed ID: 26281143
[TBL] [Abstract][Full Text] [Related]
2. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
4. Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts.
Lawrence C; Willicombe M; Brookes PA; Santos-Nunez E; Bajaj R; Cook T; Roufosse C; Taube D; Warrens AN
Transplantation; 2013 Jan; 95(2):341-6. PubMed ID: 23197178
[TBL] [Abstract][Full Text] [Related]
5. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
Kimball PM; McDougan FA; King A
Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
[TBL] [Abstract][Full Text] [Related]
6. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
7. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic analysis of acute vascular rejection cases after renal transplantation.
Shimizu T; Tanabe T; Omoto K; Ishida H; Tanabe K
Transplant Proc; 2012 Jan; 44(1):230-5. PubMed ID: 22310621
[TBL] [Abstract][Full Text] [Related]
9. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
10. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
Haas M; Mirocha J; Reinsmoen NL; Vo AA; Choi J; Kahwaji JM; Peng A; Villicana R; Jordan SC
Kidney Int; 2017 Mar; 91(3):729-737. PubMed ID: 28104301
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Intravenous Immunoglobulin Therapy for Donor Specific Antibodies in Kidney Transplant Recipients with Acute and Chronic Graft Dysfunction: Updates on Previously Reported Cohorts.
Alfonso J; Gralla J; Klem P; Chan L; Wiseman AC; Cooper JE
Clin Transpl; 2014; ():161-70. PubMed ID: 26281141
[TBL] [Abstract][Full Text] [Related]
13. Expression patterns of B cells in acute kidney transplant rejection.
Carpio VN; Noronha Ide L; Martins HL; Jobim LF; Gil BC; Külzer AS; Loreto Mda S; Gonçalves LF; Manfro RC; Veronese FV
Exp Clin Transplant; 2014 Oct; 12(5):405-14. PubMed ID: 25299368
[TBL] [Abstract][Full Text] [Related]
14. The clinical and molecular significance of C4d staining patterns in renal allografts.
Hayde N; Bao Y; Pullman J; Ye B; Calder BR; Chung M; Schwartz D; Alansari A; de Boccardo G; Ling M; Akalin E
Transplantation; 2013 Feb; 95(4):580-8. PubMed ID: 23274969
[TBL] [Abstract][Full Text] [Related]
15. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
16. The impact of C4d staining as a humoral injury marker.
Kara M; Demir F; Ata P; Ozel L; Gumrukcu G; Unal E; Canbakan M; Gucun M; Esadoglu V; Ozdemir E; Cemel H; Titiz MI
Transplant Proc; 2012; 44(6):1694-6. PubMed ID: 22841245
[TBL] [Abstract][Full Text] [Related]
17. C4D deposition and positive posttransplant crossmatch are not necessarily markers of antibody-mediated rejection in renal allograft recipients.
Banasik M; Boratyńska M; Nowakowska B; Haloń A; Kościelska-Kasprzak K; Drulis-Fajdasz D; Patrzałek D; Weyde W; Klinger M
Transplant Proc; 2007 Nov; 39(9):2718-20. PubMed ID: 18021967
[TBL] [Abstract][Full Text] [Related]
18. Antibody-mediated rejection and treatment in pediatric patients: one center's experience.
Gulleroglu K; Baskin E; Bayrakci US; Turan M; Ozdemir BH; Moray G; Karakayali H; Haberal M
Exp Clin Transplant; 2013 Oct; 11(5):404-7. PubMed ID: 24128133
[TBL] [Abstract][Full Text] [Related]
19. Probable C4d-negative accelerated acute antibody-mediated rejection due to non-HLA antibodies.
Niikura T; Yamamoto I; Nakada Y; Kamejima S; Katsumata H; Yamakawa T; Furuya M; Mafune A; Kobayashi A; Tanno Y; Miki J; Yamada H; Ohkido I; Tsuboi N; Yamamoto H; Yokoo T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():75-8. PubMed ID: 26031592
[TBL] [Abstract][Full Text] [Related]
20. A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.
Vo AA; Zeevi A; Choi J; Cisneros K; Toyoda M; Kahwaji J; Peng A; Villicana R; Puliyanda D; Reinsmoen N; Haas M; Jordan SC
Transplantation; 2015 Feb; 99(2):299-308. PubMed ID: 25606785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]